Ocular Complications of Diabetes Mellitus

Scott, G. I.

doi:10.1136/bjo.37.12.705

Cited by 43 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We recruited only the patients with stage Vb or VI PDR by Scott's classification in this study. 9 After extensive discussion of risks and benefits of intravitreal bevacizumab-assisted vitrectomy, each patient signed a comprehensive consent form. An intravitreal injection of 1.25 mg bevacizumab was followed by planned vitrectomy after 3-30 days.…”

Section: Methodsmentioning

confidence: 99%

Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

Ishikawa

Honda

Tsukahara

et al. 2007

Eye

104

View full text Add to dashboard Cite

Purpose To evaluate the safety and efficacy of intravitreal injection of bevacizumab advanced to vitrectomy for severe proliferative diabetic retinopathy. Methods Eight eyes of six patients (33-64 years old, all male patients) with severe proliferative diabetic retinopathy were investigated. An intravitreal injection of 1.25 mg bevacizumab was performed 3-30 days prior to planned vitrectomy. Results All cases showed minimum bleeding during surgical dissection of fibrovascular membrane. Two cases receiving bevacizumab 7 days before the surgery showed strong fibrosis and adhesion of fibrovascular membrane, resulted in some surgical complications. The cases having intravitreal bevacizumab for shorter time did not show extensive fibrosis. Conclusions The pretreatment of bevacizumab is likely effective in the vitrectomy for severe PDR. The appropriate timing of vitrectomy after bevacizumab injection should be further evaluated.

show abstract

Section: Methodsmentioning

confidence: 99%

Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

Ishikawa

Honda

Tsukahara

et al. 2007

Eye

104

View full text Add to dashboard Cite

show abstract

“…Classification of diabetic retinopathy Diabetic retinopathy was evaluated by Scott' s classification (15).…”

Section: Patientsmentioning

confidence: 99%

Glomerular Lesions in Patients with Non-Insulin-Dependent Diabetes Mellitus and Microalbuminuria.

et al. 1993

View full text Add to dashboard Cite

To evaluate the renal structural changes in non-insulin-dependent diabetes mellitus (NIDDM), we studied the renal histological findings and urinary albumin excretion in 75 patients with NIDDM.They were divided into two groups according to excretion of urinary albumin: 40 cases of normoalbuminuria and 35 cases of microalbuminuria. Renal biopsy specimens were evaluated by light microscopy. Diffuse glomerular lesions were graded on a scale of DOthrough DIV (Gellman's criteria).The incidence of microalbuminuria was 19.2% in DO, 53.3% in DI, 61.5% in DII and 100% in Dili. Grade IV lesions were not present in either group. Creatinine clearance differed significantly between the groups with and without microalbuminuria. There was no difference between the groups with normoalbuminuria and microalbuminuria in the incidence of retinopathy and hypertension, or in the urinary excretion of B2MGand NAG.Weconclude that microalbuminuria in NIDDM indicates the early morphological changes of glomerular lesions. (Internal Medicine 32: 753-757, 1993)

show abstract

“…The stage of retinopathy was identified according to Scott's classification of diabetic retinopathy [6,19], a classification based on the evolution of the lesions. The visual fields were examined by the Tübinger perimeter.…”

Section: Methodsmentioning

confidence: 99%

Hyperviscosity in Whole Blood, Plasma, and Aqueous Humor Decreased by Doxium (Calcium Dobesilate) in Diabetics with Retinopathy and Glaucoma: A Double-Blind Controlled Study

Vojniković¹

1984

Ophthalmic Res

View full text Add to dashboard Cite

50 patients with diabetes mellitus of 2–7 years’ duration were divided by a random method into 2 equal groups, one of which received 1,500 mg of Doxium (calcium dobesilate) daily for 3 months, the other group receiving a placebo. All the patients had diabetic retinopathy, open-angle glaucoma, raised intraocular pressure, and hyperviscosity of whole blood, plasma, and aqueous humor. 10 patients in each group underwent operation for glaucoma. At the end of the trial the state of the retina, the visual acuity, and the visual fields had improved, and the intraocular pressure and the 3 viscosity values had fallen to a statistically significant extent in the Doxium group compared with the initial status and with the placebo group. These results are consistent with Doxium’s known action in reducing capillary fragility, microvascular hyperpermeability, and blood viscosity.

show abstract

Ocular Complications of Diabetes Mellitus

Cited by 43 publications

References 11 publications

Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

Glomerular Lesions in Patients with Non-Insulin-Dependent Diabetes Mellitus and Microalbuminuria.

Hyperviscosity in Whole Blood, Plasma, and Aqueous Humor Decreased by Doxium (Calcium Dobesilate) in Diabetics with Retinopathy and Glaucoma: A Double-Blind Controlled Study

Contact Info

Product

Resources

About